Long-term extracorporeal bilirubin elimination: A case report on cascade resin plasmaperfusion

Blood Purification

Volumn 16, Issue 6, 1998, Pages 341-348

  Mertens, Peter Rene ^a,b   Schönfelder, Thomas ^a   Handt, Stefan ^a   Kierdorf, Horst ^a   Marschall, Hanns Ulrich ^a   Busch, Norbert ^a   Heintz, Bernhard ^a   Sieberth, Heinz Günter ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Bioartificial liver support device; Haemoperfusion; Hepatic failure; Hyperbilirubinaemia; Plasmaperfusion

Indexed keywords

ACTIVATED CARBON; ANION EXCHANGE RESIN; BILIRUBIN; DOXYCYCLINE; ERYTHROMYCIN; OMEPRAZOLE; RANITIDINE;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING; CASE REPORT; CHOLESTATIC HEPATITIS; FEMALE; HEMOPERFUSION; HUMAN; HYPERBILIRUBINEMIA; PRIORITY JOURNAL;

BILE ACIDS AND SALTS; CHARCOAL; CHOLESTASIS; DISSEMINATED INTRAVASCULAR COAGULATION; DOXYCYCLINE; EPILEPSY, GENERALIZED; ERYTHROMYCIN; EXTRACORPOREAL CIRCULATION; FATAL OUTCOME; HEMATOMA, SUBDURAL; HEPATIC ENCEPHALOPATHY; HEPATITIS, TOXIC; HUMANS; HYPERBILIRUBINEMIA; KIDNEY FAILURE, ACUTE; LIVER FAILURE; OMEPRAZOLE; PNEUMONIA; RANITIDINE; RESINS, PLANT; SHOCK, SEPTIC; THROMBOPHLEBITIS;

EID: 0032418440     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000014354     Document Type: Article

References (40)

1. Miller D, Keeton G, Webber B, Saunders S: Jaundice in severe bacterial infections. Gastroenterology 1976;71:1799-1805.
2. Green RM, Beier D, Gollan JL: Regulation of hepatocyte bile salt transporters by endotoxin and inflammatory cytokines in rodents. Gastroenterology 1996;111:193-198.
3. Green RM, Whiting JF, Rosenbluth AB, Beier D, Gollan JL: Interleukin-6 inhibits hepatocyte taurocholate uptake and sodium-potassium-adenosinetriphosphatase activity. Am J Physiol 1994;267:G1094-G1100.
4. Dawson JL: Acute postoperative renal failure in obstructive jaundice. Ann R Coll Surg Engl 1968;42:163-170.
5. Kew MC, Brunt PW, Varma RR, Hourigan KJ, Williams HS, Sherlock S: Renal and intrarenal blood-flow in cirrhosis of the liver. Lancet 1971;2:504-510.
6. Papper S: Hepatorenal syndrome; in Epstein M (ed): The Kidney in Liver Disease, ed 2. New York, Elsevier Biomedical, 1983, pp 87-106.
7. Cowger ML, Labbe RF: Bilirubin toxicity in cultured mammalian cells. Fed Proc 1964;23:233-238.
8. Wiessman G: Studies of lysosomes. IV. The effect of neutral steroids and bile acids on lysosomes in vitro. Biochem Pharmacol 1965;14:525-529.
9. O'Grady JG, Alexander GJ, Hayllar KM, Williams R: Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-445.
10. Ascher NL, Lake JR, Emond JC: Liver transplantation for fulminant hepatic failure. Arch Surg 1993;128: 677-682.
11. Kong LB, Chen S, Demetriou AA, Rozga J: Matrix-induced liver cell aggregates for bioartificial liver use. Int J Artif Organs 1996;19:72-78.
12. Rozga J, Demetriou AA: Artificial liver. Evolution and future perspec-tives. ASAIO J 1995;41:831-837.
13. Gerlach JC: Development of a hybrid liver support system: A review. Int J Artif Organs 1996;19:645-654.
14. O'Grady JG, Gimson AES, O'Brien CJ, Pucknell A, Hughes RD, Williams R: Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988;94:1186-1192.
15. Suenaga M, Yoshikatsu O, Sugiura H, Kokuba Y, Uehara S, Mori K, Yamaguchi S, Yamanaka N, Oda O: Effect of therapeutic plasma exchange and bilirubin adsorption on serum bilirubin subfractions in hepatic failure. Ther Plasmapher 1993;12:175-179.
16. Geiger H, Klepper J, Lux P, Heidland A: Biochemical assessment and clinical evaluation of a bilirubin adsorbent column (BR-350) in critically ill patients with intractable jaundice. Int J Artif Organs 1992;5: 35-39.
17. Hughes RD, Pucknell A, Routley D, Langley PG, Wendon JA, Williams R: Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure. Int J Artif Organs 1994;17:657-662.
18. Lee MG, Hanchard B, Williams NP: Drug-induced acute liver disease. Postgrad Med J 1989;65:367-370.
19. Jochem V, Kirkpatrick R, Greenson J, Brogan M, Sturgis T, Cook-Glenn C: Fulminant hepatic failure related to omeprazole. Am J Gastroenterol 1992;87:523-525.
20. Hautekeete ML: Hepatotoxicity of antibiotics. Acta Gastroenterol Belg 1995;58:290-296.
21. Neuberger J: Drug-induced jaundice. Gastroenterology 1989;3:447-466.
22. Kaplowitz N, Aw TY, Simon FR, Stolz A: Drug-induced hepatotoxicity. Ann Intern Med 1984;104:826-839.
23. Vial T, Goubier C, Bergeret A, Cabrera F, Evreux JC, Descotes J: Side effects of ranitidine. Drug Saf 1991; 6:94-117.
24. Lienart F, Morissens M, Jacobs P, Ducobu J: Doxycycline and hepatotoxicity. Acta Clin Belg 1992;47: 205-208.
25. Gholson CF, Warren GH: Fulminant hepatic failure associated with intravenous erythromycin lactobionate. Arch Intern Med 1990;150: 215-216.
26. Makowka L, Cramer DV, Hoffman A, Breda M, Sher L, Eiras-Hreha G, Tuso PJ, Yasunaga C, Cosenza CA, Cosenza CA, Wu GD, Chapman FA, Podesta L: The use of a pig liver xenograft for temporary support of a patient with fulminant hepatic failure. Transplantation 1995;59:1654-1659.
27. Nyberg SL, Peshwa MV, Payne WD, Hu WS, Cerra FB: Evolution of the bioartificial liver: The need for randomized clinical trials. Am J Surg 1993;166:512-521.
28. Nyberg SL, Misra SP: Hepatocyte liver-assist systems - A clinical update. Mayo Clin Proc 1998;73:765-771.
29. Matthew HW, Basu S, Peterson WD, Salley SO, Klein MD: Performance of plasma-perfused, microencapsulated hepatocytes: prospects for extracorporeal liver support. J Pediatr Surg 1993;28:1423-1427.
30. Rozga JR, Holzman MD, Ro M-S, Griffin DW, Neuzil DF, Giorgio T, Moscioni AD, Demetriou AA: Development of a hybrid bioartificial liver. Annals Surg 1993;217:502-511.
31. Gerlach J, Encke J, Hole O, Muller C, Courtney J, Neuhaus P: Hepatocyte culture between three dimensional arranged biomatrix-coated independent artificial capillary systems and sinusoidal endothelial cell coculture compartments. Int J Artif Organs 1994;17:301-306.
32. Sussmann NL, Gislason G, Conlin CA, Kelly JH: The Hepatix extracorporeal liver assist device: Initial clinical experience. Artif Organs 1994;18:390-396.
33. Catapano G: Mass transfer limitations to the performance of membrane bioartificial liver support devices. Int J Artif Organs 1996;19: 18-35.
34. Rozga J, Podesta L, LePage E, Morisani E, Moscioni AD, Hoffman A, Sher L, Villamil F, Woolf G, McGrath M, Kong L, Rosen H, Lanman T, Vierling J, Makowka L, Demetriou AA: A bioartificial liver to treat severe acute liver failure. Ann Surg 1994;5:538-546.
35. Ellis AJ, Hughes RD, Wendon JA, Dunne J, Langley PG, Kelly JH, Gislason GT, Sussman NL, Williams R: Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996; 24:1446-1451.
36. Watanabe FD, Mullon CJ, Hewitt WR, Arkadopoulos N, Kahaku E, Eguchi S, Khalili T, Arnaout W, Shackleton CR, Rozga J, Sobmon B, Demetriou AA: Clinical experience with a bioartificial liver in the treatment of severe liver failure: A phase I clinical trial. Ann Surg 1997;225: 484-491.
37. Wu TW: Bilirubin analysis - state of the art and future prospects. Clin Biochem 1984;17:221-229.
38. Schiff L, Schiff ER: Diseases of the Liver, ed 7. Philadelphia, Lippincott, 1993.
39. Davenport A, Will EJ, Davison AM: Adverse effects on cerebral perfusion of prostacyclin administered directly into patients with fulminant hepatic failure and acute renal failure. Nephron 1991;59:449-454.
40. Hawker F: Liver dysfunction in critical illness. Anaesth Intensive Care 1991;19:165-181.